Reveri Company Profile

Background

Reveri, established in 2019, is a digital health company specializing in self-hypnosis applications designed to help users manage stress, alleviate pain, improve sleep, and modify behaviors. Co-founded by Dr. David Spiegel, a renowned psychiatrist from Stanford University, and Ariel Poler, a seasoned Silicon Valley entrepreneur, Reveri aims to democratize access to the therapeutic benefits of hypnosis through technology. The company's mission is to make hypnosis mainstream, enabling individuals worldwide to better manage stress, chronic pain, insomnia, overeating, and addiction.

Key Strategic Focus

Reveri's strategic focus centers on delivering clinically-backed, personalized self-hypnosis programs via its mobile application. The app offers interactive sessions that guide users into a state of focused attention, making their subconscious minds more receptive to positive suggestions. These sessions, typically lasting between five to thirteen minutes, address various issues such as stress, anxiety, insomnia, chronic pain, and addiction. By leveraging the expertise of Dr. Spiegel and integrating advanced technology, Reveri targets individuals seeking non-pharmacological interventions for mental and physical health challenges.

Financials and Funding

As of February 2022, Reveri secured $1.8 million in seed funding led by InReach Ventures, with participation from Background Capital and angel investors including Bobby Lo, Joe Greenstein, Andrew Artz, Joseph Rubinsztain, and Eduardo Vilar. This capital infusion is intended to enhance the app's features, expand its user base, and further research into the efficacy of self-hypnosis for various health conditions.

Technological Platform and Innovation

Reveri's platform is distinguished by its integration of clinical hypnosis techniques into a user-friendly mobile application. The app employs interactive recordings and utilizes technologies such as Alexa to create a personalized experience that mirrors in-person hypnosis sessions. Notably, the app includes a feature to assess users' hypnotizability, tailoring sessions to individual responsiveness. This innovative approach allows users to access effective self-hypnosis sessions conveniently, providing immediate relief without side effects.

Leadership Team

Dr. David Spiegel: Co-Founder and Chief Scientific Officer. Dr. Spiegel is a Professor of Psychiatry and Behavioral Sciences at Stanford University and directs the Stanford Center on Stress and Health. With over 45 years of clinical and research experience in hypnosis, he brings unparalleled expertise to Reveri.

Ariel Poler: Co-Founder and Board Member. A seasoned entrepreneur and investor, Poler has founded and led multiple internet companies and served on the boards of pioneering technology firms, including Strava and Returnly. His focus on human augmentation aligns with Reveri's mission to enhance well-being through technology.

Louise Troen: Chief Marketing Officer. Troen brings over a decade of experience in marketing and communications, having held leadership roles at Bumble and Headspace. Her expertise in brand building and consumer behavior is instrumental in positioning Reveri within the health-tech sector.

Competitor Profile

Market Insights and Dynamics

The digital mental health market is experiencing significant growth, driven by increasing awareness and acceptance of non-pharmacological interventions for mental well-being. Self-hypnosis applications are gaining traction as accessible tools for managing stress, anxiety, and other health issues. Reveri operates within this expanding market, offering a unique blend of clinical expertise and technological innovation.

Competitor Analysis

Reveri faces competition from several companies in the digital mental health space:

HypnoBox: Offers self-hypnosis sessions targeting stress, trauma, insomnia, and anxiety. The app provides guided sessions that lead users into a state of focused attention, facilitating positive behavioral changes.

Oneleaf: Develops online self-hypnosis programs with input from hypnotherapists and psychologists, focusing on behavior modification and mental well-being.

Eleos Health: Provides a digital mental health platform that supports clinicians with AI-driven insights to enhance therapy sessions. While not focused solely on self-hypnosis, it represents competition in the broader digital mental health arena.

Strategic Collaborations and Partnerships

Reveri has established partnerships with leading investors and advisors to strengthen its market position and innovation capacity. The involvement of investors like InReach Ventures and Background Capital, along with angel investors such as Andrew Huberman, underscores the company's commitment to integrating scientific research with technological development.

Operational Insights

Reveri's competitive advantage lies in its foundation of clinical research and the expertise of its leadership team. The app's design focuses on user engagement and efficacy, offering interactive sessions that are both accessible and effective. By addressing a range of health issues through self-hypnosis, Reveri differentiates itself from competitors that may focus on narrower aspects of mental health.

Strategic Opportunities and Future Directions

Looking ahead, Reveri aims to expand its user base globally, leveraging its recent rebranding to enhance market presence. The company plans to introduce new content addressing emerging health concerns, such as vaping addiction, reflecting its responsiveness to public health trends. Continued investment in technology and research will support the development of more personalized and effective self-hypnosis sessions, positioning Reveri as a leader in the digital mental health space.